Erlotinib as a salvage treatment after gefitinib failure for advanced non-small-cell lung cancer patients with brain metastasis: A successful case report and review

RATIONALE: The guidelines recommended gefitinib as a first-line targeted treatment for stage IV non-small-cell lung cancer (NSCLC) patients with EGFR mutations. However, resistance to gefitinib ensues invariably and there is little evidence as for the effectiveness of subsequent salvage treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Yong, Li, Qijun, Miao, Qian, Li, Da
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238270/
https://www.ncbi.nlm.nih.gov/pubmed/34160440
http://dx.doi.org/10.1097/MD.0000000000026450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8238270/
https://www.ncbi.nlm.nih.gov/pubmed/34160440
http://dx.doi.org/10.1097/MD.0000000000026450

Ejemplares similares